Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.34 |
| ▸ | AMD1 | P17707 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745731 | 0.84 | ADORA2A (0.40) | ADORA2APIK3CAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL13575846 | 0.81 | PIK3CA (0.41) | ADORA2APIK3CAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22259414 | 0.81 | ADORA2A (0.39) | ADORA2APIK3CAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL24251660 | 0.77 | L3MBTL1 (0.42) | ADORA2AALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL29392742 | 0.77 | L3MBTL1 (0.42) | ADORA2AALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL2557546 | 0.77 | PIK3CA (0.39) | ADORA2APIK3CAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL29597929 | 0.76 | CCR4 (0.42) | PIK3CAKMT2AMEN1NUDT1HTT | |
| SCHEMBL3149912 | 0.76 | CCR4 (0.42) | PIK3CAKMT2AMEN1NUDT1HTT | |
| SCHEMBL23013102 | 0.76 | HTT (0.33) | KMT2AHTT | |
| SCHEMBL670030 | 0.72 | HTT (0.37) | KMT2AKDM4EMBOAT4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911652-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | Biogen MA Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ADORA2A 4114/4885PIK3CA 153/4885ALDH1A1 2176/4885 |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | ADORA2A 914/4885PIK3CA 1/4885ALDH1A1 4446/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ADORA2A 4114/4885PIK3CA 153/4885ALDH1A1 2176/4885 |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | ADORA2A 2166/4885PIK3CA 72/4885ALDH1A1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.